Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study

• Auteurs principaux: Yen-Chieh Lee (Auteur), Yaa-Hui Dong (Auteur), Wei-Shun Yang (Auteur), Li-Chiu Wu (Auteur), Jou-Wei Lin (Auteur), Chia-Hsuin Chang (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background: Both sodium glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular protective effects in patients with type 2 diabetes mellitus. However, the comparative risk of GLP-1RA versus SGLT-2i for major adverse limb events remains...